The Effects of Curcuma longa L., Purple Sweet Potato, and Mixtures of the Two on Immunomodulation in C57BL/6J Mice Infected with LP-BM5 Murine Leukemia Retrovirus. 2018

Soo-Jeung Park, and Dasom Lee, and Minhee Lee, and Han-Ol Kwon, and Hyesook Kim, and Jeongjin Park, and Woojin Jeon, and Minseok Cha, and Suhwa Jun, and Kwangjin Park, and Jeongmin Lee
1 Department of Medical Nutrition, Kyung Hee University , Yongin, Korea.

The immune response is stimulated to protect the body from external antigens and is controlled by several types of immune cells. In the present study, the immunomodulatory effects of Curcuma longa L., purple sweet potato, and mixtures of the two (CPM) were investigated in C57BL/6 mice infected with LP-BM5 murine leukemia virus (MuLV). Mice were divided into seven groups as follows: normal control, infected control (LP-BM5 MuLV infection), positive control (LP-BM5 MuLV infection+dietary supplement of red ginseng 300 mg/kg body weight), the original powder of C. longa L. (C; LP-BM5 MuLV infection+dietary supplement of C 189 mg/kg body weight), the original powder of purple sweet potato (P; LP-BM5 MuLV infection+dietary supplement of P 1811 mg/kg body weight), CPM Low (CPL; LP-BM5 MuLV infection+CPM 2 g/kg body weight), and CPM High (CPH; LP-BM5 MuLV infection+CPM 5 g/kg body weight). Dietary supplementation lasted for 12 weeks. Dietary supplementation of CPM inhibited LP-BM5 MuLV-induced lymphadenopathy and splenomegaly and inhibited reduction of messenger RNA (mRNA) expression of major histocompatibility complex (MHC) I and II. Moreover, CPM reduced the decrease in T- and B cell proliferation, reduced the population of CD4(+)/CD8(+) T cells, and remedied the unbalanced production of T helper-1 (Th1)/T helper-2 (Th2) cytokines in LP-BM5 MuLV-infected mice. In addition, CPM inhibited reduction of phagocytosis in peritoneal macrophages and decreased serum levels of immunoglobulin A (IgA), immunoglobulin E (IgE), and immunoglobulin G (IgG). These results suggest that CPM had a positive effect on immunomodulation in C57BL/6 mice induced by LP-BM5 leukemia retrovirus infection.

UI MeSH Term Description Entries
D008285 Major Histocompatibility Complex The genetic region which contains the loci of genes which determine the structure of the serologically defined (SD) and lymphocyte-defined (LD) TRANSPLANTATION ANTIGENS, genes which control the structure of the IMMUNE RESPONSE-ASSOCIATED ANTIGENS, HUMAN; the IMMUNE RESPONSE GENES which control the ability of an animal to respond immunologically to antigenic stimuli, and genes which determine the structure and/or level of the first four components of complement. Histocompatibility Complex,Complex, Histocompatibility,Complex, Major Histocompatibility,Complices, Histocompatibility,Complices, Major Histocompatibility,Histocompatibility Complex, Major,Histocompatibility Complices,Histocompatibility Complices, Major,Major Histocompatibility Complices
D008297 Male Males
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D009052 Leukemia Virus, Murine Species of GAMMARETROVIRUS, containing many well-defined strains, producing leukemia in mice. Disease is commonly induced by injecting filtrates of propagable tumors into newborn mice. Graffi Virus,Graffi's Chloroleukemic Strain,Leukemia Viruses, Murine,Mouse Leukemia Viruses,Murine Leukemia Virus,Murine Leukemia Viruses,Graffi Chloroleukemic Strain,Graffis Chloroleukemic Strain,Leukemia Viruses, Mouse
D010587 Phagocytosis The engulfing and degradation of microorganisms; other cells that are dead, dying, or pathogenic; and foreign particles by phagocytic cells (PHAGOCYTES). Phagocytoses
D010936 Plant Extracts Concentrated pharmaceutical preparations of plants obtained by removing active constituents with a suitable solvent, which is evaporated away, and adjusting the residue to a prescribed standard. Herbal Medicines,Plant Extract,Extract, Plant,Extracts, Plant,Medicines, Herbal
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human

Related Publications

Soo-Jeung Park, and Dasom Lee, and Minhee Lee, and Han-Ol Kwon, and Hyesook Kim, and Jeongjin Park, and Woojin Jeon, and Minseok Cha, and Suhwa Jun, and Kwangjin Park, and Jeongmin Lee
August 2015, Journal of medicinal food,
Soo-Jeung Park, and Dasom Lee, and Minhee Lee, and Han-Ol Kwon, and Hyesook Kim, and Jeongjin Park, and Woojin Jeon, and Minseok Cha, and Suhwa Jun, and Kwangjin Park, and Jeongmin Lee
February 1987, Journal of virology,
Soo-Jeung Park, and Dasom Lee, and Minhee Lee, and Han-Ol Kwon, and Hyesook Kim, and Jeongjin Park, and Woojin Jeon, and Minseok Cha, and Suhwa Jun, and Kwangjin Park, and Jeongmin Lee
January 2011, Bioscience, biotechnology, and biochemistry,
Soo-Jeung Park, and Dasom Lee, and Minhee Lee, and Han-Ol Kwon, and Hyesook Kim, and Jeongjin Park, and Woojin Jeon, and Minseok Cha, and Suhwa Jun, and Kwangjin Park, and Jeongmin Lee
January 1998, Molecular and chemical neuropathology,
Soo-Jeung Park, and Dasom Lee, and Minhee Lee, and Han-Ol Kwon, and Hyesook Kim, and Jeongjin Park, and Woojin Jeon, and Minseok Cha, and Suhwa Jun, and Kwangjin Park, and Jeongmin Lee
July 1992, Alcohol and alcoholism (Oxford, Oxfordshire),
Soo-Jeung Park, and Dasom Lee, and Minhee Lee, and Han-Ol Kwon, and Hyesook Kim, and Jeongjin Park, and Woojin Jeon, and Minseok Cha, and Suhwa Jun, and Kwangjin Park, and Jeongmin Lee
May 1992, AIDS research and human retroviruses,
Soo-Jeung Park, and Dasom Lee, and Minhee Lee, and Han-Ol Kwon, and Hyesook Kim, and Jeongjin Park, and Woojin Jeon, and Minseok Cha, and Suhwa Jun, and Kwangjin Park, and Jeongmin Lee
January 1996, Biotherapy (Dordrecht, Netherlands),
Soo-Jeung Park, and Dasom Lee, and Minhee Lee, and Han-Ol Kwon, and Hyesook Kim, and Jeongjin Park, and Woojin Jeon, and Minseok Cha, and Suhwa Jun, and Kwangjin Park, and Jeongmin Lee
December 1996, Brain research,
Soo-Jeung Park, and Dasom Lee, and Minhee Lee, and Han-Ol Kwon, and Hyesook Kim, and Jeongjin Park, and Woojin Jeon, and Minseok Cha, and Suhwa Jun, and Kwangjin Park, and Jeongmin Lee
January 1995, International immunology,
Soo-Jeung Park, and Dasom Lee, and Minhee Lee, and Han-Ol Kwon, and Hyesook Kim, and Jeongjin Park, and Woojin Jeon, and Minseok Cha, and Suhwa Jun, and Kwangjin Park, and Jeongmin Lee
October 1992, Infection and immunity,
Copied contents to your clipboard!